CD274 and non-small cell lung carcinoma: The IMpower150 study was a randomized, open-label study that evaluated the safety and efficacy of anti-PD-L1 atezolizumab in combination with carboplatin + paclitaxel with or without bevacizumab compared with treatment with carboplatin + paclitaxel + bevacizumab in chemotherapy-naive participants with Stage IV nonsquamous non-small-cell lung cancer (NSCLC).